Comparative Pharmacology
Head-to-head clinical analysis: CAMOQUIN HYDROCHLORIDE versus PRIMAQUINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMOQUIN HYDROCHLORIDE versus PRIMAQUINE PHOSPHATE.
CAMOQUIN HYDROCHLORIDE vs PRIMAQUINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
None Documented
None Documented
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Category C
Category D/X
Antimalarial
Antimalarial